Clinical trial performance benchmarks reveal an industry that’s performing worse overall than a decade ago. So, why is pharma slow in adopting new technologies to reverse these trends?
Here we review how a Risk-Based Quality Management (RBQM) approach to trial oversight can overcome many of the challenges facing clinical trial sponsors today ─ delivering the highest quality data, study performance improvements, and significant cost savings throughout their clinical trials.
This article is taken from European Pharmaceutical Contractor, November 2018, pages 40-42. © Samedan Ltd
Download the article here.